Cariprazine in Three Special Different Areas: A Real-World Experience
Cariprazine is an antipsychotic medication which received approval from the US Food and Drug Administration for the treatment of schizophrenia in September 2015. Cariprazine is a dopamine D(3) and D(2) receptor partial agonist, with a preference for the D(3) receptor. Furthermore, although to a more...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8665865/ https://www.ncbi.nlm.nih.gov/pubmed/34908838 http://dx.doi.org/10.2147/NDT.S335332 |